Sanctuary Advisors LLC Makes New $1.14 Million Investment in ANI Pharmaceuticals, Inc. $ANIP

Sanctuary Advisors LLC purchased a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the 2nd quarter, Holdings Channel.com reports. The fund purchased 13,756 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,139,000.

A number of other large investors also recently made changes to their positions in the business. Maryland State Retirement & Pension System boosted its holdings in shares of ANI Pharmaceuticals by 5.4% during the fourth quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock worth $206,000 after purchasing an additional 134 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in ANI Pharmaceuticals by 1.5% in the first quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock valued at $736,000 after purchasing an additional 143 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its position in ANI Pharmaceuticals by 1.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock worth $1,267,000 after buying an additional 198 shares during the period. Oregon Public Employees Retirement Fund lifted its position in ANI Pharmaceuticals by 5.1% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 4,086 shares of the specialty pharmaceutical company’s stock worth $323,000 after buying an additional 200 shares during the period. Finally, Federation des caisses Desjardins du Quebec boosted its stake in ANI Pharmaceuticals by 0.6% in the 4th quarter. Federation des caisses Desjardins du Quebec now owns 39,391 shares of the specialty pharmaceutical company’s stock worth $3,110,000 after buying an additional 221 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Insider Activity

In related news, SVP Ori Gutwerg sold 3,162 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $77.00, for a total transaction of $243,474.00. Following the completion of the sale, the senior vice president owned 75,534 shares of the company’s stock, valued at approximately $5,816,118. This represents a 4.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Stephen P. Carey sold 2,850 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total transaction of $231,876.00. Following the completion of the transaction, the chief financial officer owned 174,693 shares in the company, valued at $14,213,022.48. The trade was a 1.61% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 24,387 shares of company stock worth $1,947,625. Insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Trading Down 1.4%

Shares of ANIP opened at $73.51 on Friday. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. The firm has a market capitalization of $1.69 billion, a P/E ratio of 15.84 and a beta of 0.44. The stock’s fifty day simple moving average is $79.81 and its 200 day simple moving average is $78.69. ANI Pharmaceuticals, Inc. has a twelve month low of $70.15 and a twelve month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping the consensus estimate of $2.04 by $0.17. The company had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The firm’s revenue was up 25.8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have commented on ANIP. Wall Street Zen cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Canaccord Genuity Group cut their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Guggenheim decreased their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Finally, Weiss Ratings downgraded shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $105.83.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.